Ikaros cooperates with Notch activation and antagonizes TGFβ signaling to promote pDC development

PLoS Genet. 2018 Jul 12;14(7):e1007485. doi: 10.1371/journal.pgen.1007485. eCollection 2018 Jul.

Abstract

Plasmacytoid and conventional dendritic cells (pDCs and cDCs) arise from monocyte and dendritic progenitors (MDPs) and common dendritic progenitors (CDPs) through gene expression changes that remain partially understood. Here we show that the Ikaros transcription factor is required for DC development at multiple stages. Ikaros cooperates with Notch pathway activation to maintain the homeostasis of MDPs and CDPs. Ikaros then antagonizes TGFβ function to promote pDC differentiation from CDPs. Strikingly, Ikaros-deficient CDPs and pDCs express a cDC-like transcriptional signature that is correlated with TGFβ activation, suggesting that Ikaros is an upstream negative regulator of the TGFβ pathway and a repressor of cDC-lineage genes in pDCs. Almost all of these phenotypes can be rescued by short-term in vitro treatment with γ-secretase inhibitors, which affects both TGFβ-dependent and -independent pathways, but is Notch-independent. We conclude that Ikaros is a crucial differentiation factor in early dendritic progenitors that is required for pDC identity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid Precursor Protein Secretases / metabolism
  • Animals
  • Bone Marrow Transplantation
  • Cell Differentiation / genetics*
  • Cell Line
  • Dendritic Cells / physiology*
  • Down-Regulation
  • Hematopoietic Stem Cells / physiology
  • Ikaros Transcription Factor / genetics
  • Ikaros Transcription Factor / metabolism*
  • Mice
  • Mice, Transgenic
  • Monocytes / physiology
  • Mutation
  • Receptors, Notch / metabolism*
  • Signal Transduction / genetics
  • Transforming Growth Factor beta / metabolism*
  • Up-Regulation

Substances

  • Receptors, Notch
  • Transforming Growth Factor beta
  • Zfpn1a1 protein, mouse
  • Ikaros Transcription Factor
  • Amyloid Precursor Protein Secretases

Grants and funding

This work was supported by grants from the Agence Nationale de la Recherche (ANR-07-MIME-018-02 to PKa), the Conférence de Coordination Inter-Régionale du Grand-Est of the Ligue contre le Cancer (CCIRGE-2014 to PKi and 0001K-2016 to SC) and institutional funds from INSERM, CNRS, University of Strasbourg and the ANR-10-LABX-0030-INRT grant. JM received pre-doctoral fellowships from the Ministry of Technology and Research and Fondation ARC; CS a master fellowship from the Fondation pour la Recherche Médicale (FRM-DEA20140630557) and GC a pre-doctoral fellowship from the IGBMC PhD programme (ANR-10-LABX-0030-INRT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.